Your Shopping Cart Is Empty
| Report Code: A00386 | Aug 2020 | Pages: 290 | ||
| Tables: 120 | Charts: 64 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Immunoprotein Diagnostic Testing Market
Request Now !The global immunoprotein diagnostic testing market was valued at $10,136.40 million in 2019 and is projected to reach $18,387.19 million by 2027, registering a CAGR of 6.6% from 2020 to 2027. Immunoproteins are the proteins used as a target for immunological probes or therapies. Immunoprotein diagnostic testing is the procedure of diagnosing the level of immunoproteins in the body for the analysis of diseases related to specific proteins such as immunoglobulin, pre-albumin, and others.
The growth of the global immunoprotein diagnostic testing market is propelled by increase in incidence & prevalence of infectious and chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services. In addition, technological advancements in immunodiagnostic instruments and introduction of novel automated systems are all set to augment the growth of immunoprotein diagnostic testing market during the forecast years. On the contrary, the complex regulatory framework for the approval of various immunoprotein diagnostic tests limits the growth of the market. Conversely, ongoing development in the condition-specific assays & tests and the need for early diagnosis in the emerging economies across the world provide profitable opportunities for the market growth.
The immunoprotein diagnostic testing market is segmented on the basis of type, application, technology, and region. Based on technology, the immunoprotein diagnostic testing market is classified into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. Under the enzyme-linked immunosorbent assay, the market is further divided into chemiluminescence immunoassay, fluorescence immunoassay, and colorimetric immunoassay. Based on type, the market is categorized into C-reactive protein diagnostic test, complement system protein diagnostic test, pre-albumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. Applications of immunoprotein diagnostic testing covered in the study include autoimmune disease testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.
COVID-19 pandemic has raised up a critical challenge for the entire healthcare industry verticals, thereby impacting the immunoprotein diagnostic testing market as well. The market is currently facing newer challenges such as intermittent supply chain events in manufacturing, producing and distributing diagnostic kits and assays across the globe. Besides, trade restrictions and unavailability of human resources have further complicated the distribution of these test kits to the consumers. However, this deleterious impact is being remunerated by the increasing demand of these products for COVID-19 detection. Furthermore, pharmaceutical companies are presently granted emergency-use authorization for diagnostic kits and assays in order to cope up with the ongoing pandemic crisis. This has boosted the demand for diagnostic testing in several countries, thereby driving the growth of the immunoprotein diagnostic testing market. The overall, impact of the pandemic is expected to remain positive for the key players in the market, owing to the increasing number of COVID-19 cases as well as the ongoing R&D regarding the potential use of immunoproteins for developing antibodies against the SARS-CoV-2 virus.
Based on technology, the global immunoprotein diagnostic testing market is segmented into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. Enzyme based immunoassay segment was the highest contributor to the global immunoprotein diagnostic testing market. This was attributed to growing use of immunoassays in cancer, POC IVD testing, infectious disease testing, therapeutic drug level monitoring, and the introduction of novel biomarkers. Advantages of ELISA, include long shelf life and ease of use, resulting in increased acceptance of these tests among academic and industrial sectors.
Based on type, the market is divided into C-reactive protein diagnostic tests, complement system protein diagnostic tests, pre-albumin diagnostic tests, haptoglobin diagnostic tests, immunoglobulin diagnostic tests, free light chain diagnostic tests and others. Immunoglobulin diagnostic tests segment was the largest revenue contributor, owing to increasing incidences of auto-immune diseases across the world.
Based on application, the global immunoprotein diagnostic testing market is categorized into autoimmune testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Infectious disease testing segment was the largest revenue contributor, due to higher prevalence of infectious diseases such as hepatitis B, hepatitis C, HIV-1, HIV-1/2, and human T-lymphotropic virus types I & II.
Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The North America immunoprotein diagnostic testing market accounted for the highest market share of 40.56% in 2019, and is expected to maintain this trend during the forecast period due to increase in demand for quick diagnostic services to detect chronic diseases, ongoing trend of preventive healthcare, and rise in the number of drug abuse and allergy cases. The Asia-Pacific immunoprotein diagnostic testing market is expected to grow at a CAGR of 7.7% during the forecast period, owing to increase in the number of patients suffering from chronic diseases and improvement in healthcare facilities in the region. The key players profiled in the report include Abbott Laboratories, Abcam PLC, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Enzo Life Sciences, Ortho Clinical Diagnostics, Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific.
Key Benefits For Stakeholders
Key Market Segments
By Type
By Application
By Technology
By Region
Immunoprotein Diagnostic Testing Market Report Highlights
| Aspects | Details |
|---|---|
| By TECHNOLOGY |
|
| By Type |
|
| By APPLICATION |
|
| By Region |
|
| Key Market Players | Siemens AG, Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG (Roche Diagnostics), Ortho Clinical Diagnostics, Abcam plc., Thermo Fisher Scientific Inc., Enzo Biochem, Inc., Abbott Laboratories, Diasorin S.P.A, Danaher Corporation |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.1.Key benefits for stakeholders
1.2.Key market segments
1.3.Research Methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market Definition and Scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s Five Forces Analysis
3.4.Market Dynamics
3.4.1.Drivers
3.4.1.1.Increasing incidence of chronic and infectious diseases
3.4.1.2.Technological advancements
3.4.2.Restraint
3.4.2.1.Stringent Regulations
3.4.3.Opportunities
3.4.3.1.Lucrative opportunities from emerging economies
3.4.3.2.Development of condition-specific assays and tests
3.5.COVID-19 Impact Analysis on Market
CHAPTER 4:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY
4.1.Overview
4.1.1.Market size and forecast
4.2.Radioimmunoassay (RIA)
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Immunoturbidity assay
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Immunoprotein Electrophoresis
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Enzyme Based Immunoassay
4.5.1.Key market trends and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.5.3.1.Chemiluminescence Immunoassay (CLIA)
4.5.3.2.Immunofluorescence Assay
4.5.3.3.Colorimetric Immunoassay (CI)
4.6.Others
4.6.1.Key market trends and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
CHAPTER 5:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast, by type
5.2.C-reactive protein diagnostic tests
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Complement system protein diagnostic tests
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Pre-albumin diagnostic tests
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Haptoglobin diagnostic tests
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
5.6.Immunoglobulin diagnostic tests
5.6.1.Market size and forecast
5.6.2.Market analysis, by country
5.7.Free light chain diagnostic tests
5.7.1.Market size and forecast
5.7.2.Market analysis, by country
5.8.Others
5.8.1.Market size and forecast
5.8.2.Market analysis, by country
CHAPTER 6:IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Autoimmune Testing
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Infectious Disease Testing
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Allergy Testing
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.Endocrine Testing
6.5.1.Market size and forecast
6.5.2.Market analysis, by country
6.6.Oncology Testing
6.6.1.Market size and forecast
6.6.2.Market analysis, by country
6.7.Toxicology Testing
6.7.1.Market size and forecast
6.7.2.Market analysis, by country
6.8.Others
6.8.1.Market size and forecast
6.8.2.Market analysis, by country
CHAPTER 7:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by technology
7.2.4.Market size and forecast, by type
7.2.5.Market size and forecast, by application
7.2.6.U.S.
7.2.6.1.U.S. market size and forecast, by technology
7.2.6.2.U.S. market size and forecast, by type
7.2.6.3.U.S. market size and forecast, by application
7.2.7.Canada
7.2.7.1.Canada market size and forecast, by technology
7.2.7.2.Canada market size and forecast, by type
7.2.7.3.Canada market size and forecast, by application
7.2.8.Mexico
7.2.8.1.Mexico market size and forecast, by technology
7.2.8.2.Mexico market size and forecast, by type
7.2.8.3.Mexico market size and forecast, by application
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Market size and forecast, by technology
7.3.4.Market size and forecast, by type
7.3.5.Market size and forecast, by application
7.3.6.Germany
7.3.6.1.Germany market size and forecast, by technology
7.3.6.2.Germany market size and forecast, by type
7.3.6.3.Germany market size and forecast, by application
7.3.7.France
7.3.7.1.France market size and forecast, by technology
7.3.7.2.France market size and forecast, by type
7.3.7.3.France market size and forecast, by application
7.3.8.UK
7.3.8.1.UK market size and forecast, by technology
7.3.8.2.UK market size and forecast, by type
7.3.8.3.UK market size and forecast, by application
7.3.9.Italy
7.3.9.1.Italy market size and forecast, by technology
7.3.9.2.Italy market size and forecast, by type
7.3.9.3.Italy market size and forecast, by application
7.3.10.Spain
7.3.10.1.Spain market size and forecast, by technology
7.3.10.2.Spain market size and forecast, by type
7.3.10.3.Spain market size and forecast, by application
7.3.11.Rest of Europe
7.3.11.1.Rest of Europe market size and forecast, by technology
7.3.11.2.Rest of Europe market size and forecast, by type
7.3.11.3.Rest of Europe market size and forecast, by application
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by technology
7.4.4.Market size and forecast, by type
7.4.5.Market size and forecast, by application
7.4.6.Japan
7.4.6.1.Japan market size and forecast, by technology
7.4.6.2.Japan market size and forecast, by type
7.4.6.3.Japan market size and forecast, by application
7.4.7.China
7.4.7.1.China market size and forecast, by technology
7.4.7.2.China market size and forecast, by type
7.4.7.3.China market size and forecast, by application
7.4.8.India
7.4.8.1.India market size and forecast, by technology
7.4.8.2.India market size and forecast, by type
7.4.8.3.India market size and forecast, by application
7.4.9.Rest of Asia-Pacific
7.4.9.1.Rest of Asia-Pacific market size and forecast, by technology
7.4.9.2.Rest of Asia-Pacific market size and forecast, by type
7.4.9.3.Rest of Asia-Pacific market size and forecast, by application
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by technology
7.5.4.Market size and forecast, by type
7.5.5.Market size and forecast, by application
7.5.6.Brazil
7.5.6.1.Brazil market size and forecast, by technology
7.5.6.2.Brazil market size and forecast, by type
7.5.6.3.Brazil market size and forecast, by application
7.5.7.South Africa
7.5.7.1.South Africa market size and forecast, by technology
7.5.7.2.South Africa market size and forecast, by type
7.5.7.3.South Africa market size and forecast, by application
7.5.8.Rest of LAMEA
7.5.8.1.Rest of LAMEA market size and forecast, by technology
7.5.8.2.Rest of LAMEA market size and forecast, by type
7.5.8.3.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
8.1.Abbott Laboratories
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.Abcam plc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product Portfolio
8.2.5.Business performance
8.3.Bio-Rad Laboratories, Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Danaher Corporation
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.Diasorin S.P.A
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.Enzo Biochem, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.F. Hoffmann-La Roche AG (Roche Diagnostics)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Ortho Clinical Diagnostics
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Key strategic moves and developments
8.9.Siemens AG
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Thermo Fisher Scientific Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 02.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR RADIOIMMUNOASSAY (RIA), BY REGION, 2019–2027 ($MILLION)
TABLE 03.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOTURBIDITY ASSAYS, BY REGION, 2019–2027 ($MILLION)
TABLE 04.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOPROTEIN ELECTROPHORESIS, BY REGION, 2019–2027 ($MILLION)
TABLE 05.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2019–2027 ($MILLION)
TABLE 06.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019 - 2027 ($MILLION)
TABLE 08.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR C-REACTIVE PROTEIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 09.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 10.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR PRE-ALBUMIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 11.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR HAPTOGLOBIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 12.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOGLOBULIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 13.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR FREE LIGHT CHAIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 14.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 15.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR AUTOIMMUNE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 17.INFECTIOUS DISEASES CAUSED BY BACTERIA, VIRUS AND PARASITES
TABLE 18.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 19.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ALLERGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 20.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENDOCRINE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 21.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ONCOLOGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 22.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR TOXICOLOGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 23.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 24.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 25.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 26.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 27.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 28.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 29.U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 30.U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 31.U.S IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 32.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 33.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 34.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 35.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 36.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 37.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 38.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 39.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 40.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 41.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 42.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 43.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 44.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 45.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 46.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 47.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 48.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 49.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 50.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 51.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 52.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 53.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 54.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 55.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 56.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 57.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 58.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 59.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 60.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 61.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 62.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 63.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 64.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 65.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 66.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 67.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 68.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 69.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 70.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 71.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 72.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 76.ESTIMATED NUMBER OF NEW CANCER CASES, 2018
TABLE 77.SOUTH AFRICA TOP 10 CAUSES OF DEATH (2017)
TABLE 78.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 79.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 80.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 81.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 82.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 83.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 84.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 85.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 86.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 87.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 88.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 89.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 90.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 91.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 92.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 93.ABBOTT LABORATORIES PLC: PRODUCT PORTFOLIO
TABLE 94.ABCAM: COMPANY SNAPSHOT
TABLE 95.ABCAM: BUSINESS UNITS
TABLE 96.ABCAM: PRODUCT PORTFOLIO
TABLE 97.BIO-RAD: COMPANY SNAPSHOT
TABLE 98.BIO-RAD: PRODUCT SEGMENTS
TABLE 99.BIO-RAD: PRODUCT PORTFOLIO
TABLE 100.DANAHER: COMPANY SNAPSHOT
TABLE 101.DANAHER: OPERATING SEGMENTS
TABLE 102.DANAHER: PRODUCT PORTFOLIO
TABLE 103.DIASORIN: COMPANY SNAPSHOT
TABLE 104.DIASORIN: PRODUCT SEGMENTS
TABLE 105.DIASORIN: PRODUCT PORTFOLIO
TABLE 106.ENZO: COMPANY SNAPSHOT
TABLE 107.ENZO: OPERATING SEGMENTS
TABLE 108.ENZO: PRODUCT PORTFOLIO
TABLE 109.ROCHE: COMPANY SNAPSHOT
TABLE 110.ROCHE: OPERATING BUSINESS SEGMENTS
TABLE 111.ROCHE: PRODUCT PORTFOLIO
TABLE 112.ORTHO: COMPANY SNAPSHOT
TABLE 113.ORTHO: OPERATING BUSINESS SEGMENTS
TABLE 114.ORTHO: PRODUCT PORTFOLIO
TABLE 115.SIEMENS: COMPANY SNAPSHOT
TABLE 116.SIEMENS: OPERATING BUSINESS SEGMENTS
TABLE 117.SIEMENS: PRODUCT PORTFOLIO
TABLE 118.THERMO FISHER: COMPANY SNAPSHOT
TABLE 119.THERMO FISHER: OPERATING SEGMENTS
TABLE 120.THERMO FISHER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.SEGMENTATION OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 02.TOP INVESTMENT POCKETS IN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.LOW: BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE: BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW: THREAT OF NEW ENTRANTS
FIGURE 09.MODERATE: THREAT OF SUBSTITUTION
FIGURE 10.HIGH: COMPETITIVE RIVALRY
FIGURE 11.RESTRAINTS AND DRIVERS: IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 12.INFECTIOUS DISEASES PREVALENCE, 2017, (U.S.)
FIGURE 13.CHRONIC DISEASES PREVALENCE, 2017, (U.S.)
FIGURE 14.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR RADIOIMMUNOASSAY (RIA) BY COUNTRY, 2019 & 2027(%)
FIGURE 15.PREVALENCE OF DIABETES IN POPULATION (MILLIONS) AND DIABETES PREVALENCE (%)
FIGURE 16.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOTURBIDITY ASSAYS BY COUNTRY, 2019 & 2027(%)
FIGURE 17.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOPROTEIN ELECTROPHORESIS BY COUNTRY, 2019 & 2027(%)
FIGURE 18.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) BY COUNTRY, 2019 & 2027(%)
FIGURE 19.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 20.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR C-REACTIVE PROTEIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 21.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 22.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR PRE-ALBUMIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 23.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR HAPTOGLOBIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 24.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOGLOBULIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 25.MULTIPLE MYELOMA, INCIDENCES AND MORTALITY (2019)
FIGURE 26.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR FREE LIGHT CHAIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 27.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 28.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR AUTOIMMUNE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 29.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR INFECTIOUS DISEASE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 30.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ALLERGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 31.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ENDOCRINE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 32.ESTIMATED NUMBER OF INCIDENCES AND DEATHS FROM 2018 TO 2040, ALL CANCERS, BOTH SEXES, ALL AGES (2018)
FIGURE 33.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ONCOLOGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 34.ILLICIT DRUG USE AMONG PEOPLE (IN MILLION), 2018
FIGURE 35.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR TOXICOLOGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 36.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 37.NUMBER AND INCIDENCE RATE PER 100,00 POPULATION OF REPORTED HEPATITIS CASES IN U.S. (2017)
FIGURE 38.ESTIMATED NUMBER OF NEW CANCER CASES VS. DEATHS AND DISTRIBUTION (%) BY TYPE (EXCLUDES NON-MELANOMA SKIN CANCER) IN EUROPE, BOTH SEXES, 2018
FIGURE 39.PERCENTAGE OF TOTAL DEATHS ATTRIBUTED TO NCDS, ALL AGES, SOUTH ASIA (2008-2030)
FIGURE 40.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 42.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 43.ABCAM: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.ABCAM: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 45.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 47.BIO-RAD: REVENUE SHARE BY REGION, 2019(%)
FIGURE 48.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.DANAHER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 50.DANAHER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 51.DIASORIN: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.DIASORIN: REVENUE SHARE BY REGION, 2019(%)
FIGURE 53.ENZO: NET SALES, 2017–2019 ($MILLION)
FIGURE 54.ENZO: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 55.ENZO: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 56.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 57.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 58.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 59.SIEMENS: NET SALES, 2017–2019 ($MILLION)
FIGURE 60.SIEMENS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 61.SIEMENS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 62.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 63.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 64.THERMO FISHER SCIENTIFIC. REVENUE SHARE BY REGION, 2019 (%)
The immunoprotein diagnostic testing market is expected to witness a significant growth, owing to growth in diagnosis of infectious diseases and chronic diseases globally.
The adoption of immunoprotein diagnostic tests is expected to increase due to the increased prevalence of diseases such as cancer, cardiovascular diseases, allergies, urological disorders, and orthopedic diseases. In addition, rise in demand for immunoprotein diagnostic products for proteomics research is anticipated to boost the market growth. Remarkable technological advancements have been witnessed in immunoprotein testing to provide advanced diagnostic testing for patients who suffer from various diseases. Furthermore, the recent pandemic is anticipated to create an unprecedented demand for immunoprotein diagnostic kits and assays in coming months.
A. The total market value of Immunoprotein Diagnostic Testing Market is $18,387.19 million by 2027
A. The forecast period in the report is from 2020 to 2027
A. The market value of Immunoprotein Diagnostic Testing Market in 2019 was $10,136.40 Million
A. The base year for the report is 2019
A. Yes, Immunoprotein Diagnostic Testing companies are profiled in the report
A. The top companies that hold the market share in Immunoprotein Diagnostic Testing Market are Abbott Laboratories, Abcam PLC, Bio-Rad Laboratories, Danaher Corporation, Diasorin, and Roche Diagnostics
A. No, there is no value chain analysis provided in the Immunoprotein Diagnostic Testing Market report
A. Currently, the key trend in the Immunoprotein Diagnostic Testing Market is rising number of COVID-19 incidences across the globe
Start reading instantly.
This Report and over 66,983+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report